

Cluster Headache Syndrome (Cluster Headache) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/C952F765C113EN.html>

Date: March 2022

Pages: 69

Price: US\$ 2,000.00 (Single User License)

ID: C952F765C113EN

Abstracts

Cluster Headache Syndrome (Cluster Headache) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.

Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cluster Headache Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 3, 4, 6 and 3 respectively.

Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cluster Headache Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Cluster Headache Syndrome (Cluster Headache) - Overview

Cluster Headache Syndrome (Cluster Headache) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Cluster Headache Syndrome (Cluster Headache) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cluster Headache Syndrome (Cluster Headache) - Companies Involved in Therapeutics Development

Amgen Inc

Amneal Pharmaceuticals Inc

Better Life Pharmaceuticals Inc

Biohaven Pharmaceutical Holding Company Ltd

Bright Minds Biosciences Inc

CCH Pharmaceuticals ApS

Ceruvia Lifesciences LLC

Clexio Biosciences Ltd

Crossject SA

Eli Lilly and Co

H. Lundbeck AS

Havn Life Sciences Inc

Mind Medicine MindMed Inc

NeuroPharm Inc

Psirenty Inc

Shackelford Pharma Inc

Winston Pharmaceuticals Inc

Xgene Pharmaceutical Inc

Zosano Pharma Corp

Cluster Headache Syndrome (Cluster Headache) - Drug Profiles

BETR-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events
CLE-500 - Drug Profile
Product Description
Mechanism Of Action
dihydroergotamine mesylate (DHE) - Drug Profile
Product Description
Mechanism Of Action
eptinezumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
erenumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
galcanezumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
ketamine - Drug Profile
Product Description
Mechanism Of Action
History of Events
lysergic acid diethylamide - Drug Profile
Product Description
Mechanism Of Action
History of Events
NYPRG-101 - Drug Profile
Product Description
Mechanism Of Action
psilocybin - Drug Profile
Product Description
Mechanism Of Action
psilocybin - Drug Profile
Product Description
Mechanism Of Action
psilocybin - Drug Profile
Product Description
Mechanism Of Action

rimegepant sulfate ODT - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Cluster Headache Syndrome (Cluster Headache) - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Agonize 5-HT_{2A} and 5-HT_{2C} for Pain - Drug Profile

Product Description

Mechanism Of Action

SPID-001 - Drug Profile

Product Description

Mechanism Of Action

sumatriptan - Drug Profile

Product Description

Mechanism Of Action

XG-043 - Drug Profile

Product Description

Mechanism Of Action

zolmitriptan - Drug Profile

Product Description

Mechanism Of Action

History of Events

zucapsaicin - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cluster Headache Syndrome (Cluster Headache) - Dormant Projects

Cluster Headache Syndrome (Cluster Headache) - Discontinued Products

Cluster Headache Syndrome (Cluster Headache) - Product Development Milestones

Featured News & Press Releases

Nov 16, 2021: BetterLife Obtains TD-0148A behavioural pharmacology data confirming its projected non-hallucinogenic property

Sep 29, 2021: BetterLife obtains TD-0148A receptor binding data for IND-enabling pharmacology studies

Sep 27, 2021: BetterLife files patent for TD-0148A for treatment of cluster headaches and related disorders

Jun 07, 2021: Amneal announces Dihydroergotamine (DHE) autoinjector NDA for

migraines and cluster headaches

Feb 25, 2021: Emgality (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache

Jun 08, 2020: Phase 2 clinical trial of LSD for 'Suicide Headaches' begins treating patients

Feb 27, 2020: CHMP adopted a negative opinion for an extension of indication for Emgality

Jul 11, 2019: New England Journal of Medicine publishes positive phase 3 data for Emgality (galcanezumab-gnlm) in episodic cluster headache

Jun 05, 2019: FDA approves first drug for episodic cluster headaches

May 02, 2019: Lilly to present new data at AAN 2019 on Emgality (galcanezumab-gnlm) reinforcing breadth of headache disorders portfolio

Mar 05, 2019: Lilly receives FDA Priority Review Designation for Emgality (galcanezumab-gnlm) Injection for the preventive treatment of Episodic Cluster Headache in Adults

Nov 14, 2018: Emgality receives Breakthrough Therapy Designation for prevention of Episodic Cluster Headache

May 15, 2018: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Amgen Inc, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Amneal Pharmaceuticals Inc, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Better Life Pharmaceuticals Inc, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Bright Minds Biosciences Inc, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by CCH Pharmaceuticals ApS, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Ceruvia Lifesciences LLC, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Clexio Biosciences Ltd, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Crossject SA, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Eli Lilly and Co, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by H. Lundbeck AS, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Havn Life Sciences Inc, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Mind Medicine MindMed Inc, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by NeuroPharm Inc, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Psirentity Inc, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Shackelford Pharma Inc, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Winston Pharmaceuticals Inc, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Xgene Pharmaceutical Inc, 2022

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Zosano Pharma Corp, 2022

Cluster Headache Syndrome (Cluster Headache) - Dormant Projects, 2022

Cluster Headache Syndrome (Cluster Headache) - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Cluster Headache Syndrome (Cluster Headache) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/C952F765C113EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C952F765C113EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

